This trial is evaluating whether Pomalidomide will improve 1 primary outcome, 5 secondary outcomes, and 1 other outcome in patients with Recurrent Plasma Cell Myeloma. Measurement will happen over the course of Up to 30 days after discontinuing study treatment.
This trial requires 44 total participants across 1 different treatment group
This trial involves a single treatment. Pomalidomide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Nephrotic syndrome is characterized by an imbalance between protein synthesis and protein catabolism. This leads to a decrease in water and sodium excretion. Excessive proteinuria leads to an increase in plasma protein levels. Hypervolemia and volume contraction also cause proteinuric nephritic syndrome." - Anonymous Online Contributor
"There is a high likelihood of having a neoplasm in cases of plasma cell disease that can cause bone and joint complaints. In addition, there is a high likelihood of having a myeloma with bone and joint complaints even if there have never been any signs of bone pain. Bone, joint, and muscle pain in a patient with plasma cell and no detectable calcium levels should be investigated and a specific diagnostic test should be performed." - Anonymous Online Contributor
"Although there is no agreement, neoplasms are thought to emerge from a plasma cell origin. This is most likely after multiple exposures to neoplastic polyclonal and monoclonal germline genetic or environmental stimuli. Neoplasms arise from neoplastic germline mutations or somatic hypermutation or from epigenetic and microenvironment-related factors. Neoplasts are not generated by simple proliferation. Neoplasms are mostly neoplastic cells that derive from germinal center precursor cells or from neoplastic plasma cells. Neoplastic plasmacytes are not simply immortalized neoplastic B cells or Hodgkin lymphoma cells of germinal center origin." - Anonymous Online Contributor
"There is an increased risk for neoplasms among persons with neoplasms and PLTs on the United States Veterans Health Administration primary and secondary databases of which the last is a nationally acclaimed nationwide quality of care health care system with more than 200,000 members; the first is a nationwide comprehensive health care system of which the primary focus is providing the most people and, thus, the greatest likelihood for detecting and treating cancers and PLTs." - Anonymous Online Contributor
"Neoplasms can be cured; we may not be able to prevent neoplasms, but we may be able to prevent many of the more life-threatening complications of neoplasms, plasma cell leukemias, and nonneoplastic diseases." - Anonymous Online Contributor
"Many treatments are used as part of an individual patient's treatment regimen that helps to optimize their outcome. Common treatments include chemotherapy, radiation therapy, surgery, targeted therapy, and monoclonal antibody therapy." - Anonymous Online Contributor
"There have been some promising findings for the first-line treatment of myeloma and non-Hodgkin disease. Further development of new agents and clinical trials may provide new options for patients who would benefit from a new and effective treatment." - Anonymous Online Contributor
"Results from a recent paper of patients with MM, pomalidomide at the recommended dose of 20mg twice a day had a minimal effect on disease control and treatment-related symptoms. However, it significantly improved overall QoL. Physicians evaluating MM patients should consider pomalidomide to improve the quality of life for patients with MM." - Anonymous Online Contributor
"Survival data should be considered [reference needed for further information][reference needed for further information] as it is not clear if there is a difference in survival between these patients and neoplasms, plasma cell. Additionally, there is no information on the treatment or management of these patients." - Anonymous Online Contributor
"This year has seen several developments in the use of pomalidomide for all types of lymphoid malignancies. These include an increased dose, new indications/routes of administration, improved safety data, and new indications/routes of administration. Overall, the safety and efficacy data support accelerated approval of pomalidomide for a variety of treatment types for all forms of lymphoid malignancies. Power lets you find recent pomalidomide clinical trials by type/condition/location." - Anonymous Online Contributor
"Findings from a recent study suggest that pomalidomide may be very useful as an adjuvant, postoperative, and induction therapy in MM. However, because of the lack of data about pomalidomide-associated toxicities in this population, use of pomalidomide in combination with other agents, or as a monotherapy regimen, should be further investigated." - Anonymous Online Contributor
"Pomalidomide is a safe immunomodulatory drug for people with relapsed and naïve PCL. It is well tolerated, with an overall response rate comparable to that of single agent lenalidomide." - Anonymous Online Contributor